期刊文献+

不同浓度的普伐他汀对小鼠巨噬细胞极性的影响研究 被引量:2

Effect of different concentrations of pravastatin treatment on macrophage polarity in mice
下载PDF
导出
摘要 目的探讨不同浓度的普伐他汀对小鼠巨噬细胞极性的影响。方法对小鼠骨髓来源的巨噬细胞进行体外培养,以0μmol/L普伐他汀钠组作为对照组,分别给予10、25、50μmol/L的普伐他汀钠进行药物干预24h,用酶联免疫吸附试验(ELISA)检测白细胞介素(IL)-10、IL-12的分泌,流式细胞仪检测细胞膜CD16/32、CD206的表达,荧光定量聚合酶链反应(PCR)检测Toll样受体4(TLR4)、髓样分化因子88(MyD88)、干扰素调控因子5(IRF5)mRNA的表达。结果普伐他汀钠干预后的巨噬细胞,随着普伐他汀钠的浓度升高,IL-12、CD16/32的表达下降,而IL-10、CD206的表达升高,并伴有TLR4、MyD88、IRF5mRNA的表达下调,且呈剂量依赖性。结论普伐他汀钠促进巨噬细胞向抗炎性M2型极化,该效应可能与普伐他汀钠的抗炎作用有关。 Objective To study the effect of different concentrations of pravastatin treatment on macrophage polarity in mice.Methods The mice bone marrow sources of macrophages were cultured in vitro,with the 0μmol/L sodium pravastatin group as control,by giving 10,25,50μmol/L sodium pravastatin to conduct the drug intervention for 24 h.The enzyme linked immunosorbent assay(ELISA)was used to detect the secretion of interleukin 10(IL-10)and IL-12;the flow cytometry instrument was used to detect cell membrane CD16/32,CD206expression;real time quantitative polymerase chain reaction(RT-qPCR)was adopted to detect toll-like receptor 4(TLR4),myeloid differentiation factor 88(MyD88),interferon regulatory factor 5(IRF5)mRNA expression.Results After the intervention of pravastatin sodium on macrophages,as the pravastatin sodium concentration increase,the expression of IL-12 and CD16/32 was decline,while the expression of IL-10 and CD206 was risen,which was accompanied by TLR4,MyD88,IRF5 mRNA expression down regulatyion,and a dose dependent manner.Conclusion Sodium pravastatin promote the polarization of macrophages toward an anti-inflammatory macrophage phenotype(M2),this effect may be related with the antiinflammatory effect of sodium pravastatin.
作者 谷祥任 张雁
出处 《重庆医学》 CAS 北大核心 2016年第9期1173-1175,1178,共4页 Chongqing medicine
关键词 普伐他汀 炎症 巨噬细胞极性 动脉粥样硬化 pravastatin inflammation macrophage polarity atherosclerosis
  • 相关文献

参考文献15

  • 1Tuttolomondo A,Di Raimondo D, Pecoraro R, et al. Ath- erosclerosis as an inflammatory disease[J]. Curr Pharm Des,2012,18(28) :4266-4288.
  • 2Sica A,Mantovani A. Macrophage plasticity and polariza- tion: in vivo veritas[J]. J Clin Invest, 2012,122 (3) : 787- 795.
  • 3Khallou-Laschet J, Varthaman A, Fornasa G, et al. Macro- phage plasticity in experimental atherosclerosis[J]. PLoS One, 2010,5 (1) : e8852.
  • 4Pradel LC, Mitchell AJ, Zarubica A, et al. ATP-binding cassette transporter hallmarks tissue macrophages and modulatescytokine-triggered polarization programs [J]. Eur J Immunol,2009,39(8) :2270-2280.
  • 5Vats D, Mukundan L, Odegaard JI, et al. Oxidative metab- olism and PGC -lbeta attenuate maerophage-mediated in- flammation[J]. Cell Metab, 2006,4 (1) : 13-24.
  • 6Johan F. Immunity,atherosclerosis and cardiovascular dis- ease[J]. BMC Med, 2013,11 : 117.
  • 7Glass CK, Witztum JL. Atherosclerosis.. the road ahead [J]. Cell, 2001,104(4).. 503-516.
  • 8Wilson HM. Macrophages heterogeneity in atherosclerosis implications for therapy[J]. J Cell Mol Med, 2010,14 (8) .- 2055-2065.
  • 9Gelosa P,Cimino M, Pignieri A, et al. The rote of HMG- CoA reductase inhibition in endothelial dysfunction and inflammation[J]. Vase Health Risk Manag, 2007,3 (5) : 567-577.
  • 10Sposito AR,Aguiar Filho GB, Aarao AR, et al. Statins in acute coronary syndromes[J]. Arq Bras Cardio, 2011,97 (4) :350-356.

同被引文献22

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部